Gene · 7913
NIH grants1,044
NIH grants whose papers are about the gene, through NIH's grant-paper links.
261 to 280 of 1,044
Download this page as JSON| Grant | Title | DEK papers | Newest fiscal year |
|---|---|---|---|
| R25GM086262 | University of Michigan Postbaccalaureate Research Education Program (UM PREP) | 1 | 2024 |
| R35CA232097 | Towards Precision Immuno-Oncology: Unraveling the Genomic Determinants and Mechanisms Underlying Immunotherapy Efficacy and Resistance | 1 | 2024 |
| R35GM138181 | Regulation and Function of Histone H3K36 Methylation in Mammalian Chromatin | 1 | 2024 |
| T32CA009666 | Research Training in Academic Medical Oncology | 1 | 2024 |
| U01CA243004 | Multiscale analysis of metabolic inflammation as a driver of breast cancer | 1 | 2024 |
| U01CA260851 | Phase separation-induced nuclear organization in ALT Cancer | 1 | 2024 |
| U01DA053691 | Mechanisms of Genome Organization in Brain Development and Behavior | 1 | 2024 |
| U24CA232979 | Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCI | 1 | 2024 |
| UL1TR001412 | University of Buffalo Clinical and Translational Science Institute | 1 | 2024 |
| UL1TR001425 | Center for Clinical and Translational Science and Training | 1 | 2024 |
| UL1TR001442 | UC San Diego Clinical and Translational Research Institute | 1 | 2024 |
| UL1TR001449 | UNM HSC Clinical and Translational Science Center | 1 | 2024 |
| ZIAAG000361 | NRF2 interactions with SIRT1 and its role on caloric restriction | 1 | 2024 |
| R01CA177910 | Novel regulation of PI3K/Akt to direct targeted breast cancer therapies | 5 | 2023 |
| R01AI064478 | Immunological characterization of the P. vivax DBP | 3 | 2023 |
| P50CA092131 | UCLA SPORE in Prostate Cancer | 2 | 2023 |
| P50CA100632 | SPORE University of Texas M. D. Anderson Cancer Center-Leukemia | 2 | 2023 |
| R01GM085490 | Cofactor-Mediated DNA Binding by the NF-kappaB Dimers | 2 | 2023 |
| R01GM104135 | Role of ADP-ribosylation in Stress Granules | 2 | 2023 |
| R01GM112846 | The role of weak multivalent interactions and phase separation in SPOP tumor suppressor function | 2 | 2023 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7913/grants?page=14